INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Delaney Mark E reported DGX

SVP & Chief Commercial Officer · QUEST DIAGNOSTICS INC · QUEST DIAGNOSTICS INC — Non-Qualifed Stock Option (right to buy)

Side
M
Value
$1.13M
Shares
7,846
Price
$144.47
Executed
Nov 18, 2025
Disclosed
Nov 20, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 18 executedNov 20, 2025 disclosed

DGX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+10 / 25

$1.1M reported value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DGX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    39
    Carol D. MillerRSelf
    DGXQUEST DIAGNOSTICS INC
    Sale
    		SELL$15K – $50KMar 10, 2025Aug 13, 2026
    traded Mar 10, 2025
    		+521dHOUSE PTR

    Evidence

    39
    Julie JohnsonDJoint
    DGXQUEST DIAGNOSTICS INC
    Purchase
    		BUY$1,001 – $15KOct 30, 2025Aug 5, 2026
    traded Oct 30, 2025
    		+279dHOUSE PTR

    Evidence

    35
    Julie JohnsonDJoint
    DGXQUEST DIAGNOSTICS INC
    Sale
    		SELL$1,001 – $15KOct 30, 2025Aug 5, 2026
    traded Oct 30, 2025
    		+279dHOUSE PTR

    Evidence

    9
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    9,853 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$53K
    252 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    12
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$54K
    259 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    17
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    2,135 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    19
    KK
    Kuppusamy KarthikSVP, Clinical Solutions
    DGXQUEST DIAGNOSTICS INC
    Small acquisition
    		L$2,936
    16 sh
    		Jan 28, 2026Feb 20, 2026
    traded Jan 28, 2026
    		+23dSEC FORM 4

    Evidence

    13
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    1,586 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$43K
    205 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Tax withholding
    		F$48K
    230 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    15
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Small acquisition
    		L$2,753
    15 sh
    		Jan 28, 2026Feb 20, 2026
    traded Jan 28, 2026
    		+23dSEC FORM 4

    Evidence

    5
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Grant or award
    		A—
    7,332 sh
    		Feb 18, 2026Feb 20, 2026
    traded Feb 18, 2026
    		+2dSEC FORM 4

    Evidence

    0
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$14K
    100 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    26
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Open-market sale · 10b5-1 plan
    		SELL$1.49M
    7,946 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    0
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$14K
    100 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    20
    DE
    Delaney Mark ESVP & Chief Commercial Officer
    DGXQUEST DIAGNOSTICS INC
    Option exercise · 10b5-1 plan
    		M$1.13M
    7,846 sh
    		Nov 18, 2025Nov 20, 2025
    traded Nov 18, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001955265-25-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 18, 2025
    Published
    Nov 20, 2025
    Ingested by INSIDER
    Nov 5, 04:32 UTC
    Last re-read
    Nov 5, 04:32 UTC

    Extracted facts

    Filer
    Delaney Mark E
    Role
    SVP & Chief Commercial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    QUEST DIAGNOSTICS INC — Non-Qualifed Stock Option (right to buy)
    Ticker
    DGX
    Shares
    7,846
    Price per share
    $144.47
    Value
    $1,133,512
    Execution date (reported)
    Nov 18, 2025
    Owned after transaction
    0 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 7,846
    • Price: $144.47

    = $1,133,512

    What this establishes

    Delaney Mark E filed this Form 4 reporting a option exercise of DGX on Nov 18, 2025. It became public on Nov 20, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP & Chief Commercial Officer
    Delaney Mark Ecik:0001955265
    Issuer
    QUEST DIAGNOSTICS INCcik:0001022079

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.